Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients with Colorectal Cancer Liver Metastases

Mahati Mokkarala, Christopher Noda, Christopher Malone, Raja Ramaswamy, Olaguoke Akinwande

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: To compare outcomes for patients with colorectal cancer liver metastases (CRCLM) treated by drug-eluting bead chemoembolization (DEB-TACE) or radioembolization (TARE). Patients and Methods: A single-center retrospective review was carried out on 202 patients with CRCLM, treated by DEB-TACE (n=47) or TARE (n=155) patients. Propensity-matching yielded 44 pairs. Paired statistical analysis was performed on matched pair demographics, treatment response, and survival. Results: Patients treated with DEB-TACE had worse extra-hepatic metastasis (68.1 vs. 47.7%, p=0.014) and ≥10 liver lesions (42.2 vs. 68.8%, p=0.001). Matched patients treated with DEB-TACE had a trend towards worse toxicity (27% vs. 9.1% (p=0.057). Index DEB-TACE treatment was not a prognostic factor for overall survival (hazard ratio=0.94, 95% confidence intervaI=0.54-1.65; p=0.83). Conclusion: In the matched CRCLM cohort, there was a trend towards worse toxicity post-DEB-TACE treatment, but it was not an independent prognostic factor for survival.

Original languageEnglish
Pages (from-to)3071-3077
Number of pages7
JournalAnticancer research
Volume39
Issue number6
DOIs
StatePublished - Jan 1 2019

Keywords

  • Colorectal cancer liver metastases
  • Drug-eluting bead chemoembolization
  • Propensity matching
  • Radioembolization
  • Survival outcomes

Fingerprint Dive into the research topics of 'Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients with Colorectal Cancer Liver Metastases'. Together they form a unique fingerprint.

  • Cite this